one intensification cycle of high-dose cytarabine and etoposide (HAE). The patient received a prophylactic cranial irradiation and intrathecal therapy with cytarabine. Allogeneic stem cell transplantation was not performed because of the lack of a HLAidentical sibling donor. A maintenance therapy with 6-thioguanine and cytarabine was given. The patient remained in remission and was discharged from hospital after 8 months of treatment. After 6 months, the patient was hospitalized because of weight loss, thrombocytopenia and hepatosplenomegaly. Repeated bone marrow examinations revealed no evidence for AML relapse. In the following, the patient suffered from a severe aspergillus sepsis and died due to a septic multiple organ failure with bleeding complications.
Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? Thanks to the widespread availability of multiparameter flow cytometry, 470% of patients affected by chronic lymphocytic leukemia (CLL) 1 are currently diagnosed in Rai stage 0. Accordingly, a new entity, called monoclonal B-cell lymphocytosis (MBL), has been identified 2,3 when a smaller clonal B-cell population is detected in the peripheral blood of otherwise healthy subjects. A value of o5 Â 10 9 clonal B cells/l and the absence of palpable lymphadenopathy and/or organomegaly are the currently applied criteria to differentiate MBL from CLL/small lymphocytic lymphoma (SLL). 2 --4 It is now evident that CLL-like MBL represents a melting pot category as it includes very different entities 5 ranging from tiny clonal B-cell populations detected through general population studies 6 --8 to larger B-cell expansions getting medical attention after the detection of lymphocytosis (recently defined as clinical MBL, cMBL). 7 --13 Large follow-up studies demonstrated that cMBL carries a risk of progression into CLL requiring treatment of about 1 --4% per year, the occurrence of SLL being the most frequent disease evolution, detected in 15% of MBL cases. 7, 10, 11 The clinical course of cMBL is far from being clearly defined and discussion exists on whether the current guidelines could be improved to better discriminate the individuals affected by MBL from those suffering from CLL. It is matter of debate which B-cell cut-off value could better distinguish patients bound to progress and which factors (and in particular if any CLL prognostic features) might predict the risk of developing a symptomatic disease. In addition, the role of imaging study has never been specifically addressed, as the guidelines for MBL evaluation at diagnosis require only a physical exam.
To address all these issues, we took advantage of a multicenter cohort of 684 patients, previously diagnosed with Rai stage 0 CLL or cMBL and followed up at nine different centers of the Rete Ematologica Lombarda (REL) network, in Northern Italy, between January 1983 and December 2010. Participating centers are (Table 1a) .
After a median follow-up of 45 months (range 0 --306), 131 subjects progressed. As expected, cMBL subjects progressed less frequently than Rai stage 0 CLL patients (only 24/182, 13.2%, vs 107/425, 25.2%, respectively, P ¼ 0.001), and, conversely, the time to progression (TTP) was significantly longer in cMBL patients (median value not reached) than in Rai stage 0 CLL patients (151 months; Po0.001). In Rai stage 0 individuals, the cause of progression was mainly represented by a lymphocyte doubling time (LDT) o6 months (38/107 patients, 35.5%), followed by the presence of increasing lymphadenopathies (27 patients, 25.2%). In cMBL the main reasons for progression were similar though more frequently due to the presence of progressive lymphadenopathies (12/24 patients, 50.0%) followed by a LDT o6 months (6 patients, 25.0%).
Twenty-three subjects in the cMBL group and 98 among Rai stage 0 CLL required treatment (P ¼ 0.004). Again, median treatment-free survival (TFS) was not reached in the former and was 187 months among the latter (P ¼ 0.001). Three-year TFS in cMBL reached the value of 96.1% and the mean hazard of progressing to CLL requiring treatment was about 1.5% per year, while 3-year TFS in Rai stage 0 CLL was equal to 87.9% with a mean hazard of 5.2% per year (Figure 1a) . Unlike recently published series, 14 we were unable to analyze the correlation with overall survival due to the low number of deaths in our cohort (only 4 in the cMBL and 16 in the Rai stage 0 subgroup).
For the first time to our knowledge, in the present cohort, a vast majority (548/614) of patients underwent imaging studies at the time of diagnosis, including abdominal ultrasound and computed tomography scans. This is a crucial issue because previous studies 11 as well as more recent reports 15 showed that an under-recognized grey zone between SLL and cMBL may exist. This raises concerns about the fact that at least a portion of the cases classified as cMBL could represent SLL with a low and hidden nodal burden, and cast doubts on the appropriateness of a simple physical examination in the workup of cMBL patients. Our present data argue against this hypothesis, because in the vast majority of cMBL (155/165) these analyses proved to be negative excluding the presence of subclinical SLL. Only 10 cases (6.1%) had lymphadenopathies and/or hepatosplenomegaly detected merely by imaging studies. The number of latter cases was underpowered to determine whether imaging predicted differences in progression rate or type of progression within the cMBL cohort.
We then challenged the current B-cell cut-off, trying to see whether a different value could more accurately discriminate at diagnosis those patients bound to progress, given that both Rai stage 0 CLL and cMBL appear to be a mixture of individuals who will never develop clinical signs and symptoms, and real patients whose life expectancy will be affected by the disease. When we applied a receiver operating characteristic (ROC) curve analysis to B-cell concentrations of the entire population, we found that an absolute B-cell count of 10.374 Â 10 9 /l was able to identify patients requiring treatment with the most powerful predictive capacity (AUC 0.623, sensitivity 45.5%, specificity 76.9%; Po0.0001), in line with recently reported results suggesting similar values (that is, 10 Â 10 9 /l and 11 Â 10 9 /l). 9, 12 The patients with a B-cell value X10.374 Â 10 9 /l experienced a more active disease with a higher progression rate (34.7 vs 16.5%, Po0.0001), a shorter median TTP (109 months vs not reached, Po0.0001) and TFS (120 months vs not reached, Po0.0001, Figure 1b ) in comparison with those with o10.374 Â 10 9 /l. Three-year TFSs in subjects with o and X10.374 Â 10 9 B cells/l were 94.0 and 81.4%, respectively, with a risk of progression of 2.4 and 8.5% per year, respectively. Using the higher cut-off value, the difference in terms of risk of progression became larger (2.4 vs 8.5% per year) compared with the difference based on the traditional 5 Â 10 9 B cells/l threshold (1.5 vs 5.2% per year). That notwithstanding, the progression rate of the low-risk individuals with o10.374 Â 10 9 /l increased as well (2.4%) in comparison with subjects with o5 Â 10 9 /l (1.5%), creating a potential trade-off in terms of psychological distress and need for monitoring to the patients diagnosed with MBL. These results further underscore the fact that, being a continuous variable, no specific B-cell count cut-off will ever be able to precisely identify the individuals with no risk of progression.
For these reasons, we hypothesized that the study of molecular and biological prognostic markers might better hold the promise to reach this goal. In our cohort, no statistically significant differences were identified between Rai stage 0 CLL and cMBL regarding the distribution of biological prognostic parameters at diagnosis, for example, IGHV gene mutational status, CD38 expression or cytogenetic abnormalities by FISH (Table 1a) . In cMBL subgroup, as currently defined (o5 Â 10 9 /l), unfavorable cytogenetic (based on the presence of del11q or del17p) was the only factor predicting a progressive clinical course (Table 1b) , hampering further multivariate correlation. Median TTP and TFS were both 62 months in FISH-unfavourable cases and not reached among the favorable ones (Po0.001 for both values).
As expected, in the overall patient population IGHV gene mutational status, CD38 expression and cytogenetic predicted outcome (Po0.001, P ¼ 0.023 and P ¼ 0.005, respectively; Table 1b ). We combined these prognostic parameters with the B-cell count as categorical variable in a Cox regression model. At multivariate analysis, IGHV gene identity was always significant (Po0.001) regardless the B-cell cut-off. Interestingly, the 10.374 Â 10 9 /l and 10 Â 10 9 /l B-cell cut-offs had independent prognostic significance (P ¼ 0.008 and P ¼ 0.011, respectively), while the B-cell value X or o5 Â 10 9 /l was no longer relevant after adjusting for IGHV gene mutations, CD38 and FISH status (Table 1c ).
In conclusion, we here suggest that larger multicentric studies on cMBL can indeed be helpful in improving our understanding of the diagnosis and the management of this condition. We provide evidence to support the recommendation of the current guidelines that lymph node assessment by physical examination (and not imaging) is the most appropriate evaluation for the MBL workup. We do confirm that a cut-off of 10 Â 10 9 B cells/l better identifies individuals with lower risk of progression. Nevertheless, assessing the B-cell count is not enough to sharply demarcate the lowest and the highest risk categories; biological parameters (such as, in our multivariate analysis, IGHV gene mutational status) may be needed to best stratify subjects (Figure 1c) . It is likely that in a future a better understanding of the biological and molecular features of MBL/CLL will allow to define markers able to more precisely predict the fate of CLL-like B cells in each affected individual better than (or in association with) any possible different numerical cut-off value.
